MX337070B - Método para preparar un conjugado klh-egfrviii. - Google Patents

Método para preparar un conjugado klh-egfrviii.

Info

Publication number
MX337070B
MX337070B MX2012007283A MX2012007283A MX337070B MX 337070 B MX337070 B MX 337070B MX 2012007283 A MX2012007283 A MX 2012007283A MX 2012007283 A MX2012007283 A MX 2012007283A MX 337070 B MX337070 B MX 337070B
Authority
MX
Mexico
Prior art keywords
vaccine compositions
methods
present disclosure
compositions
composistions
Prior art date
Application number
MX2012007283A
Other languages
English (en)
Other versions
MX2012007283A (es
Inventor
Syed Saleem Ahmed
John Joseph Buckley Iii
Lavina Marina Lewis
Brandi Rae Osborne
Sandipan Sinha
Jennifer Marie Thorn
Ferhana Zaman
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Publication of MX2012007283A publication Critical patent/MX2012007283A/es
Publication of MX337070B publication Critical patent/MX337070B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método preparar un conjugado KLH-EGFRvIII que comprende: a) combinar KLH con un conector de entrecruzamiento bifuncional y dejar que KLH y el conector interactúen durante un tiempo que varía de 30 x 60 minutos; b) agregar un péptido que comprende la SEQ ID NO: 1 al producto de KLH activado resultante de la etapa a) para proporcionar el conjugado KLH-EGFRvIII, en donde la relación molar conector:KLH varia de 75:1 a 325:1. Un conjugado KLH-EGFRvIII producido por el método de caracterizado porque dicho conjugado presenta una densidad de epítopes en el rango de 20-80, determinando mediante el análisis de la composición de aminoácidos.
MX2012007283A 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii. MX337070B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Publications (2)

Publication Number Publication Date
MX2012007283A MX2012007283A (es) 2012-07-30
MX337070B true MX337070B (es) 2016-02-11

Family

ID=43797591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007283A MX337070B (es) 2009-12-22 2010-12-08 Método para preparar un conjugado klh-egfrviii.

Country Status (13)

Country Link
US (3) US20130034573A1 (es)
EP (2) EP3257525A3 (es)
JP (2) JP6007105B2 (es)
KR (1) KR20120120185A (es)
CN (2) CN107412754A (es)
AU (1) AU2010334428B2 (es)
CA (1) CA2785585A1 (es)
IL (1) IL220308A0 (es)
MX (1) MX337070B (es)
NZ (2) NZ629256A (es)
RU (1) RU2581020C2 (es)
SG (2) SG10201408505SA (es)
WO (1) WO2011077309A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201290804A1 (ru) * 2010-02-21 2013-03-29 БАЙЕР ХелсКер ЛЛСи Способ активации и сопряжения биомолекул
KR101502360B1 (ko) * 2013-03-20 2015-03-25 주식회사 옵티팜 신규한 국내형 돼지생식기호흡기증후군 바이러스
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
EP3823677A4 (en) * 2018-07-19 2022-06-01 Helixmith Co., Ltd. LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR NAKED DNA GENE THERAPY
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (es) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DE69532767T2 (de) 1994-11-28 2004-08-12 Thomas Jefferson University Peptid umfassend eine Sequenz aus einer Fusionsverbindungsstelle in einem mutierten EGF-Rezeptor vom Typ III
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
EP0930893B1 (en) 1996-10-11 2005-04-13 The Regents of The University of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052581A1 (en) 1997-05-20 1998-11-26 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP4101888B2 (ja) 1997-06-06 2008-06-18 ダイナバックス テクノロジーズ コーポレイション 免疫刺激オリゴヌクレオチド、その組成物およびその使用方法
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
WO1999006840A1 (en) * 1997-07-31 1999-02-11 Metra Biosystems, Inc. Collagen-peptide assay method
PT1630168E (pt) * 1997-08-27 2011-07-20 Novartis Vaccines & Diagnostic Compostos miméticos moleculares de péptidos de meningococos do serogrupo b
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ATE464907T1 (de) 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
CN1227030C (zh) 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2003068260A1 (fr) * 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
WO2004016655A1 (ja) * 2002-08-14 2004-02-26 Mitsubishi Chemical Corporation 中枢性タウ蛋白質特異的抗体
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
CA2530172A1 (en) * 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
ES2375706T3 (es) * 2003-11-14 2012-03-05 Baxter International Inc. Composiciones de alfa 1-antitripsina y métodos de tratamiento que usan tales composiciones.
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
KR100958505B1 (ko) 2004-07-18 2010-05-17 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
NZ563526A (en) * 2005-05-24 2009-02-28 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFalpha and a carrier protein
CA2628282C (en) 2005-11-02 2015-04-07 John H. Sampson Concurrent chemotherapy and immunotherapy
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
TW201731488A (zh) * 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物

Also Published As

Publication number Publication date
JP6007105B2 (ja) 2016-10-12
JP2015180667A (ja) 2015-10-15
CN107412754A (zh) 2017-12-01
AU2010334428B2 (en) 2015-05-21
JP2013515049A (ja) 2013-05-02
KR20120120185A (ko) 2012-11-01
CN102762224A (zh) 2012-10-31
AU2010334428A1 (en) 2012-07-05
EP2515934B1 (en) 2017-05-17
MX2012007283A (es) 2012-07-30
SG10201408505SA (en) 2015-02-27
EP3257525A3 (en) 2018-02-28
US20150087815A1 (en) 2015-03-26
US20130034573A1 (en) 2013-02-07
RU2012131162A (ru) 2014-01-27
EP2515934A2 (en) 2012-10-31
IL220308A0 (en) 2012-07-31
CA2785585A1 (en) 2011-06-30
WO2011077309A2 (en) 2011-06-30
WO2011077309A3 (en) 2011-10-06
NZ629256A (en) 2016-02-26
SG181628A1 (en) 2012-07-30
EP3257525A2 (en) 2017-12-20
RU2581020C2 (ru) 2016-04-10
US20190365886A1 (en) 2019-12-05
NZ600978A (en) 2014-08-29
JP6146927B2 (ja) 2017-06-14

Similar Documents

Publication Publication Date Title
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
PH12012500925A1 (en) Oral compositions containing extracts of zizyphus joazeiro and related methods
MY152711A (en) Oral compositions containing a combination of natural extracts and related methods
WO2010111409A3 (en) Pluripotent stem cells
EP4585589A3 (en) Stem cell cultures
MY165955A (en) Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
MX2012005782A (es) Procedimientos, composiciones y kits de liofilizacion.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
MX353579B (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
MX344786B (es) Composiciones y metodos para tratar enfermedad de gaucher.
MX2011003473A (es) Composiciones para el cuidado bucal.
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
MX2010000348A (es) Cultivo de celulas madre pluripotentes individuales.
IN2012DN01898A (es)
IN2012DN00581A (es)
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MY161601A (en) Films and compositions comprising the same
PH12014501369A1 (en) Oral care compositions
IN2012DN03404A (es)
WO2012075117A3 (en) Small molecule-polymer conjugates and methods of making same
ZA202106453B (en) Compositions, methods and uses for inducing viral growth
WO2010138750A3 (en) Generation of genetically corrected disease-free induced pluripotent stem cells
MX2012007283A (es) Composiciones para vacunas.
WO2012119103A3 (en) Compositions and methods for mobilization of stem cells

Legal Events

Date Code Title Description
FG Grant or registration